Hematology News

NEW ORLEANS — Emicizumab-kxwh prophylaxis appeared effective and safe for infants with severe hemophilia A without factor VIII inhibitors, according to study results presented at ASH Annual Meeting and Exposition.

Keith Hoots, MD, received ASH’s Outstanding Service Award.

NEW ORLEANS — A new clinical tool can help identify which patients with clonal hematopoiesis are at highest risk for progression to cancer, according to study results presented at ASH Annual Meeting and Exposition.

ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.

This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.

Infants with Artemis-deficient severe combined immunodeficiency improved after corrected genes in their stem cells enabled them to grow their own T cells and B cells, according to a study published in The New England Journal of Medicine.

NEW ORLEANS — The use of low-molecular-weight heparin among pregnant women with a history of recurrent miscarriage and inherited thrombophilia had no effect on the live birth rate, results from the phase 3 ALIFE2 trial showed.

The FDA lifted its partial clinical hold on bluebird bio’s sickle cell disease studies evaluating lovotibeglogene autotemcel among patients aged younger than 18 years, according to the agent’s manufacturer.

NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had clinically meaningful and significant improvement in symptoms, results of the phase 3 APPLY-PNH trial showed.

A nationwide red blood cell alloantibody exchange could reduce mortality among alloimmunized individuals with sickle cell disease, according to study results presented at ASH Annual Meeting and Exposition.